Schizophrenia Clinical Trial
Official title:
Randomized Controlled Trial of the Graduated Recovery Intervention Program for First-Episode Psychosis
This study will determine the effectiveness of the Graduated Recovery Intervention Program, a manual-based individual therapy program, in enhancing the clinical benefit of routine treatment for individuals recovering from their first episodes of psychosis.
Several mental disorders can be classified as psychotic disorders, such as schizophrenia and
manic depression. Psychosis is a defining feature of psychotic disorders, and is
characterized by delusions and hallucinations that result in extreme impairment of a
person's ability to think clearly. First-episode psychosis refers to the first time someone
experiences psychotic symptoms or a psychotic episode. The symptoms can be disturbing and
unfamiliar to those who have not previously experienced them. The person experiencing
first-episode psychosis may not understand what is happening, and may become confused and
distressed. Psychosis is treatable, however, and most people recover. Standard treatment for
psychosis entails a combination of behavioral therapy and drug therapy. GRIP is a
comprehensive psychosocial intervention for people recovering from an initial episode of
non-affective psychosis. The purpose of GRIP is to improve occupational functioning after
first-episode psychosis and promote goal pursuit and effective illness self-management. This
study will determine the effectiveness of GRIP in enhancing the clinical benefit of routine
treatment for individuals recovering from their first episodes of psychosis.
Participants in this study will be randomly assigned to receive either treatment as usual
(TAU) or TAU plus GRIP. Participants receiving TAU will meet with their case-manager and
health care providers on an as-needed basis. Participants assigned to receive TAU plus GRIP
will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments.
GRIP includes four phases, each of which focuses on one of the following topics: engagement
and wellness management; substance use; persistent symptoms; and functional recovery.
Assessments of social functioning, psychotic symptoms, attitudes toward treatment, substance
use, and hospital readmission rate will be assessed at baseline, mid-treatment,
post-treatment, and at the follow-up visit 3 months post-treatment.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |